Document is current
Any future updates will be listed below
-
Authors
Gui, Gege
Ravindra, Niveditha https://orcid.org/0000-0002-2550-493X
Hegde, Pranay S.
Andrew, Georgia
Mukherjee, Devdeep
Wong, Zoë https://orcid.org/0000-0001-6006-1233
Auletta, Jeffery J. https://orcid.org/0000-0002-1515-2141
El Chaer, Firas
Chen, Evan C.
Chen, Yi-Bin https://orcid.org/0000-0002-9554-1058
Corner, Adam
Devine, Steven M. https://orcid.org/0000-0001-7731-759X
Iyer, Sunil G.
Jimenez Jimenez, Antonio Martin https://orcid.org/0000-0003-2817-6836
De Lima, Marcos J. G. https://orcid.org/0000-0002-8568-4522
Litzow, Mark R. https://orcid.org/0000-0002-9816-6302
Kebriaei, Partow https://orcid.org/0000-0002-8607-9404
Saber, Wael
Spellman, Stephen R. https://orcid.org/0000-0002-7271-8252
Zeger, Scott L.
Page, Kristin M.
Dillon, Laura W. https://orcid.org/0000-0002-4877-9354
Hourigan, Christopher S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1ZIAHL006163)
FNIH Biomarkers Consortium project MRD in AML
- License Information
-
More Information
Article History
Received: 23 July 2024
Revised: 9 October 2024
Accepted: 11 October 2024
First Online: 6 November 2024
Competing interests
: CSH: The National Heart, Lung, and Blood Institute receives research funding for the laboratory of CSH from the Foundation of the NIH AML MRD Biomarkers Consortium. JJA: Advisory Committee: AscellaHealth and Takeda. FEC: Consultant: SPD Oncology, Amgen, Association of Community Cancer Centers; Clinical Trial Grant Support (PI) to the University of Virginia: Amgen, BMS, Celgene, SPD Oncology, Sanofi, Bristol Myers Squibb, FibroGen, PharmaEssentia, BioSight, MEI Pharma, Novartis, Arog pharmaceuticals; Travel grant: DAVA Oncology. ECC: Consultant: Rigel Pharmaceuticals and AbbVie. YBC: Consultant: Incyte, Takeda, Astellas, Editas, Novo Nordisk, Pharmacosmos, Vor. AC: Employment: Bio-Rad Laboratories. AMJJ: Funding: Abbvie. MJGDL: Advisory Board: Pfizer, Bristol Myers Squibb; Data Safety Monitoring Board: Novartis, Abbvie; Research Funding: Miltenyi Biotec. MRL: Research support: Abbvie, Astellas, Amgen, Actinium, Pluristem, Sanofi; Speakers Bureau: Beigene, Amgen; Data Safety Monitoring Committee: Biosight. PK: Consultant: Pfizer, Jazz Pharmaceuticals
: Protected health information for research was collected and maintained in CIBMTR’s capacity as a public health authority under the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. All patients provided written informed consent for participation in the National Marrow Donor Program institutional review board–approved CIBMTR database (NCT01166009) and repository (NCT04920474) research protocols. Research was performed in compliance with all applicable federal regulations pertaining to the protection of human research participants and with the approval of the CIBMTR observational research group.
